SCHEMBL2056786

SCHEMBL2056786

CC(C)(C)N(c1ccccc1)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 4/20 0.36
ALOX15 P16050 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPK1 P28482 1/20 0.36
KCNN4 O15554 1/20 0.36
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
CYP2D6 P10635 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26002503 0.89 MEN1 (0.38) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL24433604 0.85 ALDH1A1 (0.43) CYP3A4SMN1; SMN2ALDH1A1MAPK1CYP1A2
SCHEMBL20333509 0.85 MEN1 (0.35) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL26002570 0.83 MEN1 (0.38) MEN1KMT2ACYP3A4CYP2C9CYP2C19
Carbazole SCHEMBL29263416 0.81 ALDH1A1 (0.54) MEN1KMT2ASMN1; SMN2HTTALDH1A1
SCHEMBL29027385 0.79 MEN1 (0.36) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL24433605 0.79 MAOA (0.40) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL29882223 0.78 MEN1 (0.38) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL635129 0.78 MEN1 (0.42) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL45354 0.77 MEN1 (0.40) MEN1KMT2ACYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114957240-B Preparation method and application of carbonyl ring-closed arylamine fluorescent compound 广东工业大学 2024-07-19 CN claimed
CN-118027031-A Carbonyl ring-closed arylamine fluorescent compound with narrow band emission, and preparation method and application thereof 广东工业大学 2024-05-14 CN claimed
CN-117835718-A White light organic electroluminescent composition and application thereof 深圳大学 2024-04-05 CN claimed
CN-117003753-A Carbonyl arylamine pi stacking fluorescent dye and preparation method thereof 广东工业大学 2023-11-07 CN claimed
CN-116283984-A Organic thermal delay fluorescent material based on di-tert-butylaniline donor and preparation method thereof 电子科技大学 2023-06-23 CN claimed
CN-114957240-A Preparation method and application of carbonyl closed-loop arylamine fluorescent compound 广东工业大学 2022-08-30 CN claimed
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 CN claimed
CN-110590844-A Preparation method for synthesizing tenofovir alafenamide by two-step method 江西农业大学 2019-12-20 CN claimed
CN-110551153-A Preparation method for synthesizing tenofovir alafenamide by three-step method UNIV JIANGXI AGRICULTURAL 2019-12-10 CN claimed
EP-1633364-B1 PROCESSES FOR THE PRODUCTION OF SILDENAFIL BASE AND CITRATE SALT TEVA PHARMA (IL) 2008-02-27 EP claimed
JP-2007517803-A 2007-07-05 JP claimed
EP-1779852-A2 Methods for the production of sildenafil base and citrate salt TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-05-02 EP claimed
EP-1633364-A2 METHODS FOR THE PRODUCTION OF SILDENAFIL BASE AND CITRATE SALT TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-03-15 EP claimed
US-20050182066-A1 Methods for the production of sildenafil base and citrate salt TEVA PHARMACEUTICALS USA, INC. 2005-08-18 US claimed
WO-2005067936-A2 METHODS FOR THE PRODUCTION OF SILDENAFIL BASE AND CITRATE SALT TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-07-28 WO claimed
CN-114685539-B Organic compound, application thereof and organic electroluminescent device using same Beijing Dingcai Technology Co.,Ltd. (CN) 2026-05-26 CN disclosed
EP-4731689-A1 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE Covestro Deutschland AG (DE) 2026-04-29 EP disclosed
US-4636574-A Process for preparing arylisothiocyanates ETHYL CORPORATION (US) 1987-01-13 US disclosed
EP-0177916-A1 Mono-tertiary-alkylated toluenediamine and derivatives AIR PRODUCTS AND CHEMICALS, INC. (US) 1986-04-16 EP disclosed
US-4157343-A Preparation of aromatic diamines UOP INC. (US) 1979-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182066-A1 Methods for the production of sildenafil base and citrate salt PDE3A, PDE5A, PDE9A MEN1 2391/4885KMT2A 1927/4885CYP3A4 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.